FibroBiologics (FBLG) Other Working Capital Changes (2023 - 2026)
FibroBiologics (FBLG) posted quarterly Other Working Capital Changes of -$69000.0 for Q2 2026, up 51.41% year-over-year from -$45572.1 in Q2 2025, and up 61.24% on a QoQ basis from -$178000.0 in Q1 2026.
FibroBiologics (FBLG) Other Working Capital Changes (2023 - 2026) Analysis & Trends
FibroBiologics has reported Other Working Capital Changes for 4 years, with the latest figure at -$69000.0 in Q2 2026.
- Other Working Capital Changes for Q2 2026 came in at -$69000.0, up 51.41% year-over-year; the trailing twelve-month figure through Jun 2026 was -$547000.0 (down 32.13% YoY), and the FY2025 annual result was -$550000.0, down 51.93% from the prior year.
- Other Working Capital Changes advanced to -$69000.0 in Q2 2026, from -$178000.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $403000.0 in Q1 2026 and troughed at -$403000.0 in Q2 2026.
- A 4-year average of -$3750.0 and a median of -$8000.0 in 2024 frame the typical range for Other Working Capital Changes.
- The widest annual swing landed in 2025, when Other Working Capital Changes sank 109.68%; it then surged 51.41% in 2026.
- A 4-year view of Other Working Capital Changes shows it stood at -$53000.0 in 2023, then retreated by 16.98% to -$62000.0 in 2024, then sank by 109.68% to -$130000.0 in 2025, then soared by 46.92% to -$69000.0 in 2026.
- Per Business Quant data, the three most recent Other Working Capital Changes figures were -$69000.0 in Q2 2026, -$178000.0 in Q1 2026, and -$130000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | FibroBiologics | 8.15 Mn | 8.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -69,000.00 |
| Jun 30, 2026 | -69,000.00 |
| Jun 30, 2026 | -69,000.00 |
| Mar 31, 2026 | -178,000.00 |
| Mar 31, 2026 | -178,000.00 |
| Mar 31, 2026 | -178,000.00 |
| Dec 31, 2025 | -130,000.00 |
| Dec 31, 2025 | -130,000.00 |
| Dec 31, 2025 | -130,000.00 |
| Sep 30, 2025 | -170,000.00 |
| Sep 30, 2025 | -170,000.00 |
| Sep 30, 2025 | -170,000.00 |
| Jun 30, 2025 | -142,000.00 |
| Jun 30, 2025 | -142,000.00 |
| Jun 30, 2025 | -142,000.00 |
| Mar 31, 2025 | -108,000.00 |
| Mar 31, 2025 | -108,000.00 |
| Mar 31, 2025 | -108,000.00 |
| Dec 31, 2024 | -62,000.00 |
| Dec 31, 2024 | -62,000.00 |